Literature DB >> 19701553

[Hepatitis B, C, Treponema pallidum and Toxoplasma gondii co-infections in HIV infected patients].

Carlos Pérez C1, Inés Cerón A, Gino Fuentes L, Cristian Zañartu S, M Elvira Balcells M, Cristina Ajenjo H, Ricardo Rabagliati B, Jaime Labarca L, Guillermo Acuña L.   

Abstract

BACKGROUND: Some infections share common modes of transmission with HIV and have the potential to change the course of the latter. AIM: To assess the prevalence of hepatitis B virus (HBV) hepatitis C virus (HCV), Treponema palladium and Toxoplasmosis gondii co-infections in HIV-1 infected patients followed at a university hospital.
MATERIAL AND METHODS: Clinical records of HIV-positive individuals were reviewed. The analysis included: demographical data, hepatitis B surface antigen (HBsAg), IgM and IgG anti-HBc, antibodies, anti-HCV antibodies, RPR or VDRL test and IgG anti Tgondii antibodies.
RESULTS: Three hundred ninety five patients (aged 16 to 89 years, 359 males) were included in the review. Seventy nine percent had been tested for HBV status with HBsAg, and the global HIV-HBV co-infection prevalence was 6.1%. A subgroup of 190 individuals were tested for HBV infection with HBsAg and IgM/IgG anti-HBc markers. Of these, 46% fulfilled co-infection criteria: eight with acute hepatitis B, 11 with chronic hepatitis B and 69 with inactive HBV infection. The frequency of HIV-HBV co-infection was 48% and 22% among men and women respectively (NS). HCV-HN co-infection was detected in 3%, syphilis-HIV co-infection in 21% and T gondii-HIV co-infection in 26%.
CONCLUSIONS: In this cohort, HIV infection is accompanied by a high prevalence of other co-infections, particularly HBV among men.

Entities:  

Mesh:

Year:  2009        PMID: 19701553     DOI: /S0034-98872009000500007

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  6 in total

1.  Hepatitis B: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Barbara Bagnato; Maria Giulia Marino; Cristina Meleleo; Laura Serino; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

Review 2.  Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review.

Authors:  Fatima Mitiko Tengan; Karim Yakub Ibrahim; Bianca Peixoto Dantas; Caroline Manchiero; Mariana Cavalheiro Magri; Wanderley Marques Bernardo
Journal:  BMC Infect Dis       Date:  2016-11-09       Impact factor: 3.090

3.  Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis.

Authors:  Fatima Mitiko Tengan; Edson Abdala; Marisa Nascimento; Wanderley Marques Bernardo; Antonio Alci Barone
Journal:  BMC Infect Dis       Date:  2017-08-24       Impact factor: 3.090

4.  Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Authors:  Lucy Platt; Clare E French; Catherine R McGowan; Keith Sabin; Erin Gower; Adam Trickey; Bethan McDonald; Jason Ong; Jack Stone; Philippa Easterbrook; Peter Vickerman
Journal:  J Viral Hepat       Date:  2019-12-22       Impact factor: 3.728

5.  Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey.

Authors:  Thomas Weitzel; Fernanda Rodríguez; Luis Miguel Noriega; Alejandra Marcotti; Luisa Duran; Carla Palavecino; Lorena Porte; Ximena Aguilera; Marcelo Wolff; Claudia P Cortes
Journal:  PLoS One       Date:  2020-01-09       Impact factor: 3.240

6.  Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil.

Authors:  Solange Zacalusni Freitas; Caroline Cordeiro Soares; Tayana Serpa Ortiz Tanaka; Andréa Siqueira Campos Lindenberg; Sheila Araújo Teles; Marina Sawada Torres; Francisco Campello Amaral Mello; Maria Cássia Mendes-Corrêa; Flávia Savassi-Ribas; Ana Rita Coimbra Motta-Castro
Journal:  Braz J Infect Dis       Date:  2014-03-22       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.